Precede Biosciences closed an $83.5 million financing package (Series B plus a $20 million credit facility) to expand its liquid‑biopsy transcriptional platform for oncology. The Boston‑based company partners with drug developers to use its genome‑wide expression assay and machine‑learning models to identify responders, track resistance and support clinical trial patient selection. Precede said the new capital will scale lab capacity and deepen collaborations with pharma, aiming to integrate assays into ADC and radiopharmaceutical programs and to support regulatory‑grade data generation.